Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Roche to CHF 250 from CHF 265 and keeps a Sell rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition
- Piper ups Regeneron price target to $800, says Q4 report ‘good enough’
- Roche sees decline in group sales in low single digit range for FY23
- Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products